Published in Clin Cardiol on January 01, 1995
Retracted Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet (1998) 36.93
Cardiopulmonary resuscitation skills of preregistration house officers. Br Med J (Clin Res Ed) (1985) 8.45
Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology (1997) 7.81
Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ (1995) 6.28
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res (2003) 5.39
Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet (1999) 3.38
Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J (1994) 3.13
DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J Mol Biol (1996) 3.08
Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med (1999) 2.99
Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation (1997) 2.95
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Chlamydia pneumoniae and coronary heart disease. BMJ (1997) 2.73
Colour Doppler flow mapping. BMJ (1990) 2.69
Phytoremediation of soil metals. Curr Opin Biotechnol (1997) 2.60
Left atrial appendage: structure, function, and role in thromboembolism. Heart (1999) 2.52
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (1997) 2.50
Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation (2001) 2.50
Cost implications of the British Pacing and Electrophysiology Group's recommendations for pacing. BMJ (1992) 2.42
Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol (1991) 2.42
Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 2.31
The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J (1998) 2.28
Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart (2002) 2.23
The QT interval. Prog Cardiovasc Dis (2001) 2.22
Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol (1994) 2.21
Atrial arrhythmias. Lancet (1993) 2.13
The rhythm of the heart in active elderly subjects. Am Heart J (1980) 2.02
Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf (2001) 2.02
Complete denervation of the heart in a child with congenital long QT and deafness. Am J Cardiol (1988) 2.00
Cardiac arrhythmia suppression trial and flecainide. Lancet (1989) 1.98
Adjuvant xamoterol or metoprolol in patients with malignant ventricular arrhythmia resistant to amiodarone. Lancet (1989) 1.96
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
Components of heart rate variability--what they really mean and what we really measure. Am J Cardiol (1993) 1.91
Risk of patent foramen ovale for thromboembolic events in all age groups. Am J Cardiol (1992) 1.74
Atrioverter: an implantable device for the treatment of atrial fibrillation. Circulation (1998) 1.74
Effect of intravenous propranolol on QT interval. A new method of assessment. Br Heart J (1980) 1.71
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect (1995) 1.69
Relative efficacy of various physical manoeuvres in the termination of junctional tachycardia. Lancet (1988) 1.65
Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol (2000) 1.65
Classification of atrial fibrillation. Pacing Clin Electrophysiol (1997) 1.63
QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J (1996) 1.63
Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J (1989) 1.59
Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol (1991) 1.58
Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med (1996) 1.58
Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther (2008) 1.58
Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol (1992) 1.58
Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation (1989) 1.53
Limitations of rate response of an activity-sensing rate-responsive pacemaker to different forms of activity. Pacing Clin Electrophysiol (1988) 1.51
The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. Br Heart J (1984) 1.49
Catheter ablation for successful management of left posterior fascicular tachycardia: an approach guided by recording of fascicular potentials. Heart (1996) 1.47
Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants. Circulation (1992) 1.45
Cardiac catheterisation performed by a clinical nurse specialist. Heart (1997) 1.45
Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J (1998) 1.44
Atrial fibrillation begets trouble. Heart (1997) 1.43
Unrecognized dyslipoproteinemia in United Kingdom families recruited to a genetic register because of unexplained coronary heart disease. J Lab Clin Med (1994) 1.42
Do patients with neurally mediated syncope have augmented vagal tone? Am J Cardiol (1993) 1.41
Effect of magnesium sulphate in patients with unstable angina. A double blind, randomized, placebo-controlled study. Eur Heart J (1997) 1.41
Implantable cardioverter defibrillators and fitness to drive. Lancet (1994) 1.41
The Percutaneous Cardiac Mapping and Ablation Registry: final summary of results. Pacing Clin Electrophysiol (1988) 1.39
Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems? J Cardiovasc Electrophysiol (1999) 1.39
Influence of posture and reference point on central venous pressure measurement. BMJ (1991) 1.39
Effect of moderate physical exercise on noninvasive cardiac autonomic tests in healthy volunteers. Int J Cardiol (1999) 1.39
'Trauma: we care'. Anaesthesia (2008) 1.39
Predictive value of wavelet decomposition of the signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy. Eur Heart J (2000) 1.39
Current concepts in atrial fibrillation. Br J Hosp Med (1993) 1.39
Successful radiofrequency ablation of accessory pathways with the first energy delivery: the anatomic and electrical characteristics. Eur Heart J (1996) 1.38
Evaluation of the efficacy of flecainide acetate in the treatment of ventricular premature contractions. Postgrad Med J (1985) 1.38
Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation (1992) 1.38
Selection of dichotomy limits for multifactorial prediction of arrhythmic events and mortality in survivors of acute myocardial infarction. Eur Heart J (1997) 1.38
The NASPE/BPEG generic pacemaker code for antibradyarrhythmia and adaptive-rate pacing and antitachyarrhythmia devices. Pacing Clin Electrophysiol (1987) 1.37
Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J (1984) 1.35
Analysis of 12-lead T-wave morphology for risk stratification after myocardial infarction. Circulation (2000) 1.30
Hysteresis of the ventricular paced QT interval in response to abrupt changes in pacing rate. Cardiovasc Res (1988) 1.29
Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 1.29
Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections. Circulation (1991) 1.27
Heart rate variability. Clin Cardiol (1990) 1.27
Adenosine in the diagnosis of broad complex tachycardia. Lancet (1988) 1.27